Vectofusin-1 Promotes RD114-TR-Pseudotyped Lentiviral Vector Transduction of Human HSPCs and T Lymphocytes.

ABSTRACT: Ex vivo transduction of human CD34⁺ hematopoietic stem/progenitor cells (hCD34⁺ HSPCs) and T lymphocytes is a key process that requires high efficiency and low toxicity to achieve effective clinical results. So far, several enhancers have been used to improve this process. Among them, Retronectin highly meliorates VSV-G and RD114-TR pseudotyped lentiviral vector delivery in hCD34⁺ HSPCs and T lymphocytes. However, Retronectin is expensive and requires pre-coating of culture dishes or bags before cell seeding, resulting in a cumbersome procedure. Recently, an alternative transduction adjuvant has been developed, named Vectofusin-1, whose effect has been demonstrated on gene delivery to cell lines and primary hCD34⁺ HSPCs by lentiviral vectors pseu

SUBMITTER: Piovan C 

PROVIDER: S-EPMC5415310 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature